Last updated on September 2018

Drug Use Surveillance of Takecab for "Gastric Ulcer Duodenal Ulcer and Reflux Esophagitis"


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Duodenal Ulcer | and Reflux Esophagitis | Gastric Ulcer
  • Age: - 100 Years
  • Gender: Male or Female

Inclusion Criteria:

  • Participants with gastric ulcer, duodenal ulcer, and reflux esophagitis

Exclusion Criteria:

  • Participants with previous history of hypersensitivity to ingredients in Takecab tablets
  • Participants taking atazanavir sulfate or rilpivirine hydrochloride
  • Participants meeting the criteria of scarring stage (S1, S2) of endoscopic classification defined by Sakita and Miwa at the start of the treatment with Takecab tablets, in the case that the target disease is gastric ulcer or duodenal ulcer
  • Participants meeting the criteria of Grade N or Grade M of Los Angeles classification (Hoshihara's modification) at the start of the treatment with Takecab tablets, in the case that the target disease is reflux esophagitis.

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.